EUROPAC2 logo

EUROPAC2

Double blind, randomised controlled trial to investigate the efficacy of ANTOX (vers) 1.2 and MGCT (Magnesiocard®) for the treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis

EUROPAC2

Double blind, randomised controlled trial to investigate the efficacy of ANTOX (vers) 1.2 and MGCT (Magnesiocard®) for the treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis
Funding PharmaNord
Portfolio Clinical Specialties
Interventions Medicine
Randomised Yes
Status In Follow-up
Start Date 16-May-2007

Chronic pancreatitis causes significant pain and is increasingly common, however there is no good treatment proven to reduce attacks of pain. Previous evidence for the usefulness of micronutrient antioxidant therapy in recurrent pancreatitis has been suggestive but inconclusive. The usefulness of magnesium-therapy has been demonstrated only in an animal model of acute pancreatitis where it reduced the premature activation of digestive proteases in the pancreas and had a beneficial effect on the course of experimental pancreatitis.
Most pancreatitis is alcohol related but studies involving alcoholic patients are notoriously difficult to draw conclusions from. The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) is coordinated from Liverpool and represents the worlds largest registry of non-alcohol related pancreatitis. Patients on the registry are a highly committed group.
The objectives of this study are to determine the efficacy of antioxidant medication (ANTOX) and magnesium (Magnesiocard) compared to placebo in the treatment of pain in patients with pancreatitis using hereditary pancreatitis (HP) and idiopathic chronic pancreatitis (ICP) as models.